Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1997–1999. doi: 10.1128/aac.37.9.1997

Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

R S Witzig 1, S G Franzblau 1
PMCID: PMC188108  PMID: 8239620

Abstract

The MICs of ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid for clinical isolates of Mycobacterium kansasii were determined by the radiometric (BACTEC) method. All drugs except azithromycin elicited MICs for 90% of the strains tested that were lower than previously reported achievable maximum concentrations in serum. Ofloxacin, sparfloxacin, and clarithromycin had the largest maximum concentration in serum/MIC for 90% of strains ratio of the drugs tested.

Full text

PDF
1997

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berlin O. G., Young L. S., Floyd-Reising S. A., Bruckner D. A. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria. Eur J Clin Microbiol. 1987 Aug;6(4):486–487. doi: 10.1007/BF02013117. [DOI] [PubMed] [Google Scholar]
  2. Biehle J., Cavalieri S. J. In vitro susceptibility of Mycobacterium kansasii to clarithromycin. Antimicrob Agents Chemother. 1992 Sep;36(9):2039–2041. doi: 10.1128/aac.36.9.2039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chu S. Y., Sennello L. T., Bunnell S. T., Varga L. L., Wilson D. S., Sonders R. C. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother. 1992 Nov;36(11):2447–2453. doi: 10.1128/aac.36.11.2447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dailloux M., Petitpain N., Henry C., Weber M. Détermination in vitro de la sensibilité des mycobactéries aux fluoroquinolones. Pathol Biol (Paris) 1989 May;37(5):346–349. [PubMed] [Google Scholar]
  5. Davies S., Sparham P. D., Spencer R. C. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother. 1987 May;19(5):605–609. doi: 10.1093/jac/19.5.605. [DOI] [PubMed] [Google Scholar]
  6. Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
  7. Francis P. B., Jay S. J., Johanson W. G., Jr The course of untreated Mycobacterium kansasii disease. Am Rev Respir Dis. 1975 Apr;111(4):477–487. doi: 10.1164/arrd.1975.111.4.477. [DOI] [PubMed] [Google Scholar]
  8. Franzblau S. G., Biswas A. N., Harris E. B. Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae. Antimicrob Agents Chemother. 1992 Jan;36(1):92–94. doi: 10.1128/aac.36.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Franzblau S. G., Parrilla M. L., Chan G. P. Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis. 1993 Mar;61(1):66–69. [PubMed] [Google Scholar]
  10. Fuursted K., Askgaard D., Faber V. Susceptibility of strains of the Mycobacterium tuberculosis complex to fusidic acid. APMIS. 1992 Jul;100(7):663–667. doi: 10.1111/j.1699-0463.1992.tb03983.x. [DOI] [PubMed] [Google Scholar]
  11. Haneishi T., Nakajima M., Shiraishi A., Katayama T., Torikata A., Kawahara Y., Kurihara K., Arai M., Arai T., Aoyagi T. Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. Antimicrob Agents Chemother. 1988 Jan;32(1):110–116. doi: 10.1128/aac.32.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Harris G. D., Johanson W. G., Nicholson D. P. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. Am Rev Respir Dis. 1975 Jul;112(1):31–36. doi: 10.1164/arrd.1975.112.1.31. [DOI] [PubMed] [Google Scholar]
  13. Hoffner S. E., Olsson-Liljequist B., Rydgård K. J., Svenson S. B., Källenius G. Susceptibility of mycobacteria to fusidic acid. Eur J Clin Microbiol Infect Dis. 1990 Apr;9(4):294–297. doi: 10.1007/BF01968066. [DOI] [PubMed] [Google Scholar]
  14. Honeybourne D., Baldwin D. R. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother. 1992 Sep;30(3):249–260. doi: 10.1093/jac/30.3.249. [DOI] [PubMed] [Google Scholar]
  15. Hopewell P., Cynamon M., Starke J., Iseman M., O'Brien R. Evaluation of new anti-infective drugs for the treatment of disease caused by Mycobacterium kansasii and other mycobacteria. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S307–S312. doi: 10.1093/clind/15.supplement_1.s307. [DOI] [PubMed] [Google Scholar]
  16. Leysen D. C., Haemers A., Pattyn S. R. Mycobacteria and the new quinolones. Antimicrob Agents Chemother. 1989 Jan;33(1):1–5. doi: 10.1128/aac.33.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lillo M., Orengo S., Cernoch P., Harris R. L. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis. 1990 Sep-Oct;12(5):760–767. doi: 10.1093/clinids/12.5.760. [DOI] [PubMed] [Google Scholar]
  18. Rastogi N., Goh K. S. Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Antimicrob Agents Chemother. 1992 Dec;36(12):2841–2842. doi: 10.1128/aac.36.12.2841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Retsema J. A., Brennan L. A., Girard A. E. Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):834–842. doi: 10.1007/BF01975836. [DOI] [PubMed] [Google Scholar]
  20. Taburet A. M., Guibert J., Kitzis M. D., Sorensen H., Acar J. F., Singlas E. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J Antimicrob Chemother. 1990 Feb;25 (Suppl B):23–31. doi: 10.1093/jac/25.suppl_b.23. [DOI] [PubMed] [Google Scholar]
  21. Tsukamura M. [Bactericidal activity of ofloxacin against Mycobacterium kansasii]. Kekkaku. 1990 Nov;65(11):719–721. [PubMed] [Google Scholar]
  22. Van Caekenberghe D. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. J Antimicrob Chemother. 1990 Sep;26(3):381–386. doi: 10.1093/jac/26.3.381. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES